It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past 30 years due to the lack of early theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for bladder cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the wide use of the targeting peptides for intravesical theranostic techniques in bladder cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical application.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Zhejiang Chinese Medical University, HangZhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924); Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou, China (GRID:grid.506977.a) (ISNI:0000 0004 1757 7957)
2 Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou, China (GRID:grid.506977.a) (ISNI:0000 0004 1757 7957)
3 Handan Central hospital, Handan, China (GRID:grid.506977.a)
4 Zhejiang Chinese Medical University, HangZhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924)